Canoe Software Inc. develops an artificial intelligence-based software solution for financial document and data management, primarily targeting allocators and investors in alternative assets. Founded in 2013 and based in New York, the company specializes in automating the collection, organization, and categorization of investment documents. Its software enables users to extract unstructured data from these documents and integrate it into various accounting and reporting platforms, enhancing data accuracy and operational efficiency. Canoe’s services cater to a diverse clientele, including single and multi-family offices, endowments, foundations, pensions, investment consultants, wealth managers, and financial institutions. By transforming PDF reports into actionable data, Canoe aims to improve the post-investment operational, monitoring, and reporting experience for its clients.
Vendr, Inc. is a Boston-based company that provides a software-as-a-service solution designed to manage the purchasing and renewal processes of software for businesses. Founded in 2018, Vendr specializes in commercial negotiations, renewal management, and contract logistics, enabling companies to streamline their software acquisition efforts. By assisting organizations in purchasing and renewing software, Vendr helps them save both time and money, making it an essential partner for scaling companies. Its services are utilized by a range of fast-growing business-to-business and business-to-consumer companies, highlighting its effectiveness in the software procurement landscape.
Invetx, Inc. is a biotechnology company based in Boston, Massachusetts, that specializes in developing protein-based therapeutics for animal health care. The company focuses on creating biopharmaceutical solutions that apply human biotechnology advancements to veterinary medicine. Invetx aims to build a premier innovation platform for veterinary therapeutics, collaborating with leading biotechnology firms, investors, and industry experts. Its team, which includes veterinary scientists and clinicians, is dedicated to discovering and developing a diverse portfolio of therapies and technologies. The company's vision is to enhance health outcomes for both pets and farm animals by leveraging biopharma technologies in the global animal health industry.
Equip is a virtual program helping families recover from eating disorders at home with comprehensive, gold-standard care created by experts in the field and people in recovery. Equip’s five person care teams include dieticians, physicians, therapists, and mentors who deliver wrap-around support to provide families progress and lasting recovery. Kristina Saffran and Erin Parks co-founded the company in San Diego, California in 2019.
Logixboard, Inc. is a Seattle-based company founded in 2016 that offers a cloud platform designed to enhance transparency and communication for freight forwarders. The platform addresses inefficiencies in the $2 trillion freight forwarding industry, where many firms rely on outdated methods such as paper, spreadsheets, and email for tracking shipments. By integrating with existing back-office applications, Logixboard's solution serves as a digital customer engagement layer, enabling freight forwarders to streamline their operations and improve customer service. The platform empowers companies to manage and control their freight operations more effectively, ultimately reducing costs and increasing efficiency in a traditionally low-tech industry.
Leyden Labs aims to help people live their lives to the fullest. Its platform targets commonalities of viral families to protect humanity from known and future viruses. Its portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The Company’s energetic team of world-renown biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses.
Papaya is a developer of an online mobile bill payment application that simplifies financial transactions for users. The application supports various payment methods, including debit and credit cards and direct bank account transfers. It prioritizes security by encrypting personal information and payment data, ensuring compliance with HIPAA and PCI standards. In addition to its bill payment services, Papaya operates as an electronic money platform, offering digital solutions, online banking, and international payment services. This combination of features enables users to manage their financial activities efficiently and securely.
Lighthouse, operating under the name OTA Insight Ltd, specializes in providing cloud-based business intelligence solutions for the hospitality industry. Founded in 2012 and based in London, the company offers a suite of tools including Rate Insight, Parity Insight, and Revenue Insight, which help hoteliers make informed revenue and distribution decisions. These solutions utilize advanced data systems and forecasting algorithms to deliver real-time market demand forecasts, rate intelligence, and ranking analytics. With a strong emphasis on customer support, OTA Insight’s platform integrates seamlessly with various hotel management systems and data providers, supporting over 50,000 properties in 168 countries. Recognized as a leader in hospitality business intelligence, the company has garnered accolades and continues to empower hoteliers to optimize occupancy rates and enhance profitability.
AppliedVR is a leader in therapeutic virtual reality, focusing on improving patient experiences in healthcare through innovative digital health solutions. Founded in 2013 and based in Los Angeles, the company provides a virtual reality platform designed for pain and anxiety management in various settings, including hospitals and surgery centers. AppliedVR has established strategic partnerships with prominent institutions such as Cedars-Sinai and Children's Hospital Los Angeles, and its solutions have been scientifically validated, impacting over 20,000 patients across more than 250 hospitals in eight countries. The company draws on extensive academic research and collaboration with leading medical experts to develop its digital wellness platform, which addresses both chronic and acute pain, as well as anxiety related to surgical and emergency procedures. Through its ongoing product development, AppliedVR aims to create a comprehensive digital pain management platform and redefine treatment approaches for pain management both in healthcare facilities and at home.
Notable is an AI-powered healthcare startup focused on enhancing physician-patient interactions by automating and digitizing the recording of medical visits. The company's platform utilizes natural language processing and voice recognition technology to automatically capture and structure conversations between doctors and patients, facilitating the seamless update of electronic health records. Additionally, Notable's system recommends appropriate billing codes, streamlining administrative tasks for healthcare providers. By improving the efficiency of these interactions, Notable aims to allow physicians to dedicate more time to patient care rather than paperwork.
Centivo Corporation is a health plan administrator that provides innovative health insurance solutions for self-funded employers, employees, and clinicians. Founded in 2016 and based in Stamford, Connecticut, with additional offices in New York and Buffalo, the company aims to deliver high-quality, affordable healthcare by facilitating partnerships between employers and primary care teams. Centivo offers a comprehensive suite of services, including technology, claims processing, customer support, and population health management, to efficiently administer health benefits. Its model emphasizes collaboration between members and their primary care providers, encouraging cost-effective healthcare choices. Members benefit from personalized tools for patient-doctor matching and receive support through a user-friendly app and concierge services. Employers are supported by Centivo's commitment to eliminating waste and ensuring accountability in performance.
NOCD Inc. develops and operates a mobile application that connects mental health practitioners and people with obsessive compulsive disorder (OCD). Its application uses cognitive behavioral therapy techniques to assist in treating OCD patients. The company also helps OCD patients to find clinically supported treatment; and operates an online platform for OCD treatment. NOCD Inc. was founded in 2014 and is based in Chicago, Illinois.
Developer of intelligent medical devices designed for treatment of Parkinson and motor dysfunction. With research and development of intelligent monitoring and assistant devices, the company develops systematic systematic solutions to functional disorders for patients with Parkinson and motor dysfunction, enabling patients to monitor their physical activities and facilitate their movements.
Innovusion is a leading developer of image grade LiDAR sensor systems for the level 4 and 5 of the autonomous vehicle and ADAS markets. Their unique combination of range, resolution, hardware accelerated sensor fusion, compact size, ease of integration and cost effectiveness makes our products the ideal choice for the most demanding applications. We are venture-backed and headquartered in the heart of Silicon Valley.
Embark offers dog DNA testing that ends preventable diseases in dogs. It was founded by top experts in genomics, computational biology, and software design to sell an industry-leading dog DNA test. They use a clinical-grade CLIA-certified SNP chip to provide the most accurate and comprehensive results (200,000+ genetic markers) available on the market. Their data contributes to proprietary genetics research that will help dog owners optimize nutrition, exercise, allergies, and prevent a variety of heritable conditions. Their technological advantage, intellectual capital, and research-focus enable them to push canine health toward our shared vision of preventative veterinary care.
Castor is an international health-tech company that offers a cloud-based clinical data platform designed to streamline the clinical trial process for researchers around the world. Founded by CEO Derk Arts, MD, Ph.D., the platform is utilized by over 50,000 researchers in 90 countries and has facilitated more than 4,000 studies across diverse therapeutic areas such as diabetes, cardiovascular diseases, rare diseases, infectious diseases, and oncology. Researchers using Castor generate substantial amounts of data from both traditional and remote trials, having reached significant milestones of 180 million data points and 2 million enrolled patients. The company's mission is to enhance the reusability of research data, supporting AI-driven clinical trials and ultimately maximizing the impact of data to improve medical research globally.
Affinia Therapeutics Inc. is a biotechnology company focused on developing gene therapies for various diseases, particularly those affecting muscle and the central nervous system (CNS). Founded in 2019 and based in Waltham, Massachusetts, the company specializes in creating rationally designed adeno-associated virus (AAV) vectors. By integrating synthetic and systems biology with high-throughput screening and advanced resolution techniques, Affinia Therapeutics aims to address significant unmet medical needs. The company’s innovative approach allows for the development of novel gene therapies with enhanced properties, targeting the treatment of devastating diseases and improving the lives of affected individuals.
Proximie Inc., based in Bedford, Massachusetts, offers a secure software platform that facilitates virtual surgical collaboration among surgeons. By leveraging advanced telecommunication, augmented reality, artificial intelligence, and machine learning technologies, Proximie's platform enables real-time, peer-to-peer assistance during surgeries, regardless of location. This innovative approach allows surgeons to share expertise before, during, and after procedures, effectively overcoming the barriers of time and distance. Furthermore, the platform is compatible with various devices and software used in operating rooms, allowing for seamless integration and interaction. Proximie's mission is to enhance surgical knowledge and skills, enabling surgeons to refine their techniques in diverse settings, even with limited bandwidth.
1upHealth, Inc. is a health-tech company based in Boston, Massachusetts, that specializes in health data aggregation and centralization. Founded in 2017, the company offers a platform that secures data transmission between health systems and consumer applications. This platform consolidates health data from various electronic medical record systems into a digital health record controlled by the user, facilitating seamless sharing with healthcare providers. It also enables providers to access and query the most current patient data across multiple connected health systems. Additionally, 1upHealth's platform supports developers in obtaining clinical data from various clinics and hospitals, promoting better healthcare outcomes and cost reduction through enhanced data accessibility.
Zenflow, Inc. is a medical device company based in San Francisco, California, founded in 2014 by a team of Stanford University Biodesign Fellows in collaboration with leading urologists. The company focuses on developing and marketing a spring device designed to provide relief for permanent benign prostatic hyperplasia (BPH) symptoms in men. Zenflow's product addresses urinary obstruction without damaging surrounding tissues, offering a novel solution for patients and healthcare providers. The founders were motivated by the frustrations experienced by patients with existing treatment options, aiming to fulfill a significant unmet clinical need in urology.
Firefly Health, Inc. is a healthcare company based in Wellesley, Massachusetts, that specializes in primary health care services through an artificial intelligence-based platform. Founded in 2016, the company aims to redefine patient care by providing a virtual-first approach that combines advanced technology with a dedicated care team. Firefly Health offers services for common health conditions such as back pain, stomach flu, and women's health issues, facilitating live video appointments with primary care physicians without any membership fees. This model allows patients to navigate their health more effectively and make informed decisions, while enabling healthcare professionals to deliver consistent and proactive care.
OZiva is a plant-based Clean Nutrition Brand. The brand’s core differentiator lies in building a nutrition & fitness ecosystem that combines the best of ancient sciences such as Ayurveda, modern micronutrients, and an instantaneous digital community altogether.
Yisheng Biopharma Co., Ltd., a biopharmaceutical company, researches, develops, manufactures, and markets immuno-oncology products and vaccines. It offers YS-ON-001, an investigational biological product that demonstrates immuno-modulating effects, such as induction of anti-tumor cytokines, activation of NK cells, regulation of macrophage polarization, and suppression of regulatory T cells for the treatment of advanced solid tumors. Yisheng Biopharma Co., Ltd. was founded in 2002 and is based in Beijing with operations in China, the United States, Cambodia, and Singapore.
Cohort, Inc. develops software to transform chronic care management and clinical trials. The company’s clinical AI/NLP analyzes EHR, including diagnostics (normal, abnormal, and correlated), medications (labels), and clinical notes (free text) to surface context specific to the patient and condition. Its solution identifies and enrolls eligible patients, auto-generates care-plans, and automates compliance and billing operations. The company is based in New York, New York with an additional office in San Francisco, California.
Centivo Corporation is a health plan administrator that provides innovative health insurance solutions for self-funded employers, employees, and clinicians. Founded in 2016 and based in Stamford, Connecticut, with additional offices in New York and Buffalo, the company aims to deliver high-quality, affordable healthcare by facilitating partnerships between employers and primary care teams. Centivo offers a comprehensive suite of services, including technology, claims processing, customer support, and population health management, to efficiently administer health benefits. Its model emphasizes collaboration between members and their primary care providers, encouraging cost-effective healthcare choices. Members benefit from personalized tools for patient-doctor matching and receive support through a user-friendly app and concierge services. Employers are supported by Centivo's commitment to eliminating waste and ensuring accountability in performance.
Odaseva is a unified cloud data protection, compliance, and operations platform for enterprises running Salesforce. The company delivers enterprise-class data governance, providing data protection (backup and recovery, archiving, governor limits monitoring), data compliance for regulation requirements such as GDPR and data operations (Salesforce DX data extensions).
Odaseva was developed for Salesforce by Salesforce experts and is endorsed by Salesforce Ventures.
Carrot offers a fertility benefit for modern companies, focused on making fertility care easier, accessible, and more affordable. The company partners with modern companies to provide fertility coverage for the millions of employees. Through its software, Carrot helps employees to personalize a fertility plan, chat with fertility experts, order medications, and access unique content. It helps them access the care they need, such as egg freezing, in-vitro fertilization, fertility diagnoses, and more.
NodThera Limited is a biotechnology company based in Little Chesterford, United Kingdom, with additional facilities in Seattle, Washington, and Lexington, Massachusetts. Founded in 2016, the company specializes in researching and developing novel inhibitors of the NLRP3 inflammasome, a multi-protein complex involved in the body's immune response. NodThera aims to address a variety of inflammatory and neuroinflammatory diseases, including arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. Through its innovative approach to inflammasome research, NodThera seeks to contribute to the advancement of therapeutic options for these conditions.
Avalyn Pharma is a biopharma company that advances therapies for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other severe respiratory diseases. Its therapies rapidly advance AP01 for the treatment of IPF, provides additional pipeline candidates for IPF, improve the care and outcomes of severe respiratory diseases, and develop novel inhaled therapeutics.
Avalyn Pharma was established in 2011 and is headquartered in Seattle, Washington.
Rallybio, LLC is a biopharmaceutical company based in New Haven, Connecticut, that focuses on developing innovative therapies for patients with severe and rare disorders. Founded in 2018, the company is dedicated to addressing life-threatening conditions, particularly through its lead product candidate, RLYB211, which aims to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT). This rare disease can lead to uncontrolled bleeding in fetuses and newborns. Rallybio's research emphasizes the development of antibody, small molecule, and engineered protein therapies, primarily in the late discovery to early clinical stages. Through its efforts, Rallybio seeks to transform the lives of patients suffering from devastating diseases.
SonderMind Inc. provides mental health services through a digital network of therapists and care providers. Its solution connects consumers with a therapist for video telehealth or in-person sessions. Its service areas include ADHD, addiction, anorexia, anxiety, binge eating, bipolar disorder, bulimia, depression, eating disorders, grief and loss, LGBTQ, obsessive compulsive disorder (OCD), PTSD, postpartum, and schizophrenia. The company was founded in 2017 and is based in Denver, Colorado.
Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines. These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatment Xilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. The company applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts, United States.
BenchSci's vision is to bring medicine to patients 50% faster by 2025. The company empowers scientists with the world’s most advanced biomedical artificial intelligence to run more successful experiments. Backed by F-Prime, Gradient Ventures (Google’s AI fund), and Inovia Capital, BenchSci's proprietary technology accelerates science at 15 top 20 pharmaceutical companies and over 4,300 leading research centers worldwide. BenchSci is a CIX Top 10 Growth company, certified Great Place to Work®, and top-ranked company on Glassdoor.
Funnel Operation AB designs and develops software/platform that helps marketers automate their data collection. The company's products include dashboards and reports which simplify marketing reporting and analysis; data studio connector which gets marketing data from a number of ad sources; Google analytics upload which automatically uploads cost data to Google analytics; API and connectors which collect advertising data and send it anywhere; and Google sheets upload which add all advertising data to Google sheets. It caters to e-commerce companies, media agencies, brands, b2b businesses, mobile apps, and gaming companies. Funnel Operation AB was founded in 2014 and is based in Stockholm, Sweden.
Oviva AG is a digital health company that specializes in providing medical nutritional counseling services in Switzerland, Germany, and the United Kingdom. Established in 2013 and based in Ingenbohl, Switzerland, the company offers treatment for various medical conditions, including obesity, diabetes, heart disease, and digestive disorders, through both in-person consultations in clinics and remote support. Oviva UK Limited, founded in 2015 and headquartered in London, focuses on digitally-enabled behavior change programs for diet and lifestyle-related health issues. The company has developed a smartphone application that enables clients to communicate with dietitians, maintain a photo food diary, monitor their health goals, and access personalized educational materials. This technology-enabled approach aims to improve health outcomes for patients while reducing healthcare costs by minimizing the need for in-clinic visits and preventing complications associated with chronic conditions.
Snapdocs, Inc. is a real estate technology company that provides a digital platform designed to streamline the mortgage closing process. Founded in 2012 and based in San Francisco, California, Snapdocs connects lenders, title and escrow companies, notary publics, and home buyers to enhance collaboration and efficiency in real estate transactions. The platform features advanced automation and standardized workflows, allowing participants to choose their preferred closing methods while improving accuracy and consumer satisfaction. It also enables notary signing agents to showcase their qualifications, helping them attract potential clients. By simplifying mortgage loan closings and improving the overall borrower experience, Snapdocs empowers its users to operate more effectively and transparently in a competitive market.
CareStack is a single all-in-one platform on the cloud that combines dental practice management, patient engagement, practice marketing, and data analytics. CareStack is currently used by large and growing practices as an all-in-one solution to increase productivity, minimize costs, and improve patient dental care. CareStack's mission is to help dentists to have a better practice and a better life. Through their technology-led offerings, CareStack will elevate dental offices to a higher degree of financial success.
Insilico Medicine, Inc. is an artificial intelligence company based in Rockville, Maryland, specializing in drug discovery, biomarker development, and aging research. Founded in 2014, the company leverages advanced AI techniques, including generative adversarial networks and deep learning, to create novel molecular structures for various diseases. Insilico Medicine has developed a comprehensive end-to-end pipeline for drug discovery, which encompasses all stages from initial research to clinical trials. Its notable platforms include Pharma.AI, which offers machine learning services to various sectors, and Young.AI, which integrates predictors of age. The company is actively engaged in internal drug discovery programs targeting conditions such as cancer, Alzheimer's disease, and diabetes. Additionally, Insilico Medicine has partnered with Life Extension to produce nutraceutical products using bioinformatics and deep learning. It serves a diverse clientele, including academia, pharmaceutical companies, and cosmetic firms, while also providing consumer-facing applications to enhance health and longevity.
Insilico Medicine, Inc. is an artificial intelligence company based in Rockville, Maryland, specializing in drug discovery, biomarker development, and aging research. Founded in 2014, the company leverages advanced AI techniques, including generative adversarial networks and deep learning, to create novel molecular structures for various diseases. Insilico Medicine has developed a comprehensive end-to-end pipeline for drug discovery, which encompasses all stages from initial research to clinical trials. Its notable platforms include Pharma.AI, which offers machine learning services to various sectors, and Young.AI, which integrates predictors of age. The company is actively engaged in internal drug discovery programs targeting conditions such as cancer, Alzheimer's disease, and diabetes. Additionally, Insilico Medicine has partnered with Life Extension to produce nutraceutical products using bioinformatics and deep learning. It serves a diverse clientele, including academia, pharmaceutical companies, and cosmetic firms, while also providing consumer-facing applications to enhance health and longevity.
Buoy Health, Inc. is a health technology company based in Boston, Massachusetts, with an additional office in New York. Founded in 2014, Buoy Health specializes in artificial intelligence-driven digital health solutions that assist individuals in managing their health and healthcare options. The company offers a personalized online healthcare chatbot, known as Buoy Assistant, which analyzes symptoms, facilitates initial triage, and provides treatment recommendations. This platform enables users to conduct real-time assessments of their symptoms while simplifying the navigation of the healthcare system. Additionally, Buoy Health provides resources for employees through its Buoy Dashboard, allowing them to research benefits, access wellness programs, and connect with in-network providers. The service is available 24/7, making self-diagnosis and healthcare navigation straightforward and accessible.
ABK Biomedical Inc. is a Canadian company founded in 2012, based in Halifax, that focuses on the development of embolotherapeutic products aimed at treating uterine fibroids, hypervascular tumors, and arteriovenous malformations. The company integrates clinical market insights with advanced biomaterials to enhance treatment options for patients undergoing embolization, a procedure utilized in interventional radiology. ABK Biomedical is committed to innovating and improving these medical procedures to provide better outcomes for patients suffering from these conditions.
The leading provider of cyber risk management software, RiskLens empowers business executives, risk officers and CISOs to manage their organization's cyber risk from the business perspective by quantifying it in financial terms. RiskLens was founded in 2011 and is headquartered in Spokane, Washington.
Vestwell is a digital retirement platform founded in 2016 and based in New York, New York. The company simplifies the offering and administration of 401(k) plans by addressing common challenges faced by advisors, employers, and employees. Vestwell streamlines the process through seamless plan design, automated onboarding, and efficient administration, while also providing flexible investment strategies at competitive prices. By serving as a single point of contact, Vestwell modernizes retirement offerings, focusing on the best interests of both plan sponsors and participants.
Quicko Technosoft Labs Private Limited (also known as Whatfix) is a digital adoption platform that helps enterprises and businesses simplify their training and support efforts with easily accessible contextual information. Its platform is built with real-time interactive guidance technology at its core which helps users achieve optimal performance by providing just-in-time guidance that enables them to perform tasks quickly and efficiently.
Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing precision genetic medicines for serious diseases. It utilizes its proprietary base editing technology, which allows for targeted modifications at the single base level in the genome without causing double-stranded breaks in DNA. Beam's therapeutic pipeline includes treatments for sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, pediatric acute myeloid leukemia, alpha-1 antitrypsin deficiency, glycogen storage disorder 1A, and various ocular and central nervous system disorders. The company aims to provide long-lasting cures through its innovative approaches, which include gene correction, gene modification, gene activation, gene silencing, and multiplex editing. Beam Therapeutics was founded in 2017 and is committed to advancing the field of genetic medicine through research and clinical collaborations, including a partnership with Magenta Therapeutics.
Singular Genomics is a venture capital-backed biotech company in La Jolla, California. It fosters a dynamic, fast-paced, results-oriented environment where they offer employees the opportunity to make a significant impact in a rapidly expanding company. Singular Genomics is inventing at the forefront of genomics, one of the world’s fastest-growing industries.
The company is located in the center of the Biotech hub on the Torrey Mesa close to the Pacific Ocean and next door to prestigious institutions like the Salk Institute, Scripps, Sanford Burnham, and UCSD.
Genomics PLC develops algorithms and software solutions that focus on cancer, microbes, and rare diseases. Its solutions allow governments and healthcare providers to transform healthcare provisions for their citizens and members; pharmaceutical and biotechnology clients to de-risk the drug development process; clinicians and doctors to improve diagnoses and treatment options; and research laboratories and genome analysts to process results accurately. The company was incorporated in 2014 and is based in Oxford, United Kingdom.
Avidity Biosciences is a biopharmaceutical company specializing in the development of oligonucleotide-based therapies known as antibody oligonucleotide conjugates (AOCs). These therapies aim to address the limitations of traditional oligonucleotide treatments by combining the tissue selectivity of monoclonal antibodies with the precision of oligonucleotide therapies. Avidity's lead product candidate, AOC 1001, targets myotonic dystrophy type 1, a rare genetic muscle disorder. The company's development pipeline also includes programs focused on treating various muscle diseases, such as muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. Additionally, Avidity is exploring therapeutic applications for immune and other cell types, leveraging its proprietary AOC platform to reach previously undruggable tissues and effectively target the genetic underpinnings of these conditions. Founded in 2012, Avidity Biosciences is headquartered in La Jolla, California.
Devoted Health is a new healthcare company serving seniors. Aiming to launch Medicare Advantage plans in 2019, their mission is to build a healthcare solution good enough for Mom. They will be devoted to the health and wellness of their members by helping them navigate the health care system with personal guides, by utilizing world-class technology to enable a simplified experience, and by partnering with top providers for better health outcomes.
Axoni is a New York-based technology firm focused on capital markets, specializing in distributed ledger solutions. Founded in 2013 by experts in distributed ledger technology and cryptography, Axoni serves major financial institutions and capital markets service providers. The company's offerings include the deployment of distributed ledger technology, custom smart contract development, and advanced analytics tools. Their software integrates traditional financial technologies with blockchain capabilities, providing market information and in-depth trend analysis. This comprehensive approach enables investment funders, exchange operators, and professional traders to enhance their systems for managing legal records, lifecycle events, and cash flow calculations.
RiskRecon is the only continuous vendor monitoring solution that delivers risk-prioritized action plans custom-tuned to match your risk priorities, providing the world’s easiest path to understanding and acting on third-party cyber risk. Partner with RiskRecon to build your scalable, third-party risk management program to realize dramatically better risk outcomes. To learn more about RiskRecon’s approach, request a demo or visit the website at www.riskrecon.com.
Simon Data is the enterprise Customer Data Platform (CDP) that empowers brands to deliver data-driven, personalized customer experiences anywhere.The platform leverages enterprise-scale big data and machine learning to power customer communications in any channel. Simon’s unique approach allows brands to develop and deliver incredible personalization capabilities without needing to build and maintain massive bespoke data infrastructure. At Simon, our goal is to improve and optimize customer experiences by making the entire process, experimentation through analysis, a data-driven one.
WelbeHealth is a healthcare organization dedicated to enhancing the quality of life for frail seniors through the PACE (Program of All-Inclusive Care for the Elderly) model. Founded by experienced physician entrepreneurs, the company provides comprehensive medical and social care, ensuring that participants receive coordinated support that includes medical and dental care, therapy services, transportation, and meal provisions. By focusing on the diverse needs of the elderly population, WelbeHealth aims to help them live longer, healthier, and more independent lives. The leadership team comprises professionals from prominent payer and provider organizations, reflecting a commitment to innovative and compassionate care. Through its holistic approach, WelbeHealth strives to unlock the potential of vulnerable seniors in the community, fostering an environment of empathy and support.
Unison is a provider of home-ownership investments used for long-term financing. Its investments offer long-term investments in individual residential properties through their innovative programs in exchange for the opportunity to share gain or loss in the home's value when they decide to sell that enable applicants to buy homes without interest or monthly payments. It was founded in 2004 and is headquartered in San Francisco, California.
Benchling, Inc. is a developer of a cloud-based informatics platform tailored for life sciences research and development. The platform encompasses a range of integrated applications that enable scientists to design, share, and document experiments efficiently. Key offerings include an electronic lab notebook for experiment documentation, a biological registration system for managing inventory like plasmids and antibodies, and analytical tools for visualizing and collaborating on structured data. Benchling's software supports cutting-edge research techniques such as CRISPR and CAR-T immunotherapy, facilitating advancements in biotherapeutics, biofuels, and biomaterials. The company's solutions are utilized by researchers in biotech and pharmaceutical companies, as well as academic and government labs, streamlining workflows and enhancing collaboration across various research projects. Founded in 2012, Benchling is headquartered in San Francisco, California.
Tempest Therapeutics is a biotechnology company that focuses on small molecule therapeutics that modulate anti-tumor immunity pathways. The company has a balanced and deep pipeline consisting of first-in-class and best-in-class small molecule therapeutics, which modulate distinct pathways relevant to mounting an effective anti-tumor response.
Tempest Therapeutics was established in 2011 and is headquartered in San Francisco, California.
The Protenus healthcare compliance analytics platform uses artificial intelligence to audit every access to patient records for the nation’s leading health systems. Providing healthcare leaders full insight into how health data is being used, and alerting compliance teams to policy violations, Protenus helps our partner hospitals make decisions about how to better protect their data, their patients, and their institutions. Learn more at Protenus.com and follow us on Twitter @Protenus.
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company’s gene therapy approach seeks to transform a patient’s hematopoietic stem cells into a gene-modified drug product to treat the patient’s disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company’s clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.
Semma Therapeutics, Inc. is focused on developing innovative cell therapies for patients with Type 1 diabetes, aiming to provide alternatives to insulin injections. The company emerged from research by Professor Douglas Melton, which led to the discovery of a method for generating billions of functional, insulin-producing beta cells in the laboratory. This breakthrough technology has been exclusively licensed to Semma Therapeutics, which is now dedicated to creating a cell-based therapy that combines these proprietary cells with advanced devices to effectively replace the missing beta cells in diabetic patients without the need for immunosuppression. Established in 2014 and headquartered in Cambridge, Massachusetts, Semma Therapeutics operates as a subsidiary of Vertex Pharmaceuticals and is committed to bringing its novel therapeutic solutions to clinical settings, ultimately enhancing the quality of life for individuals living with diabetes.
Stride Health, Inc. operates a health benefits platform that allows independent workers and part-time employees to select and enroll in affordable health coverage. It offers dental plans, drive plans, and doctor and prescription insurance plans. The company serves customers in the United States. Stride Health, Inc. was formerly known as Covered, Inc. and changed its name to Stride Health, Inc. in March 2013. The company was incorporated in 2013 and is based in San Francisco, California.
Artemis Health Inc. is a health data analytics company that focuses on providing self-insured employers with actionable insights into their benefits programs. The company operates a platform that enables users to identify issues within their benefits, share findings with stakeholders, and implement solutions to enhance their offerings while tracking the effectiveness of these solutions. Founded in 2013 and headquartered in Salt Lake City, Utah, Artemis Health aims to improve the healthcare system in the United States by empowering employers to leverage their own benefits data to reduce spending and enhance employee benefits.
Amphora Medical is a Minnesota-based developer of medical devices and instruments. The company is currently working on a novel cystoscopic device that has the potential to improve bladder function and quality of life for people with Overactive Bladder Syndrome (OAB). It was founded in 2011 and is headquartered in Minneapolis, Minnesota, United States.
Wellframe is a hospital and healthcare it provides a digital health management solutions that include care management support, digital concierge solutions, and transformation services. It helps healthcare organizations by providing solutions that enable them to support people longitudinally between traditional clinical interactions.
The company was founded in 2011 and headquartered in Boston, Massachusetts, United States.
Checkmate Pharmaceuticals, Inc., a biotechnology company, develops novel immunotherapies for the treatment of cancer. It engages in the field of CpG oligonucleotides and validates an approach that combines the ability of CpG DNA to activate an anti-tumor T-cell response with checkpoint inhibition to overcome a tumor’s ability to mute the immune response. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.
Quovo Inc. is a data platform that specializes in providing financial analytics and data management solutions primarily for small and mid-sized investors. Founded in 2009 and based in New York, Quovo offers a service that automatically gathers, normalizes, and reconciles portfolio data from a wide range of financial institutions, including retail brokerages and custodians. Its offerings include tools for client onboarding, payment processing, and comprehensive insights into consumer financial accounts from over 14,000 institutions. Quovo's technology features automated data repair, manual entry support, and security measures, enabling clients such as family offices, advisors, and foundations to track investment strategies and generate reports. The company also supports fintech firms and leading financial services providers by enhancing customer relationships through streamlined access to financial data. Quovo operates as a subsidiary of Plaid Inc. since January 2019.
Medwell Ventures Private Limited provides specialty home healthcare services in India. It focuses on various therapeutic areas. The company offers various wellness and care programs ranging from preventive screening to home healthcare and palliative care. It provides bedside nursing care at home, as well as 24×7 medical services, such as physician consultation, nursing care, laboratory sample collection and reporting, physiotherapy, medical devices, ambulance services, pharmacy support, and related medical services. The company’s integrated healthcare delivery system serves customers across varied age and health profiles. Medwell Ventures Private Limited was founded in 2014 and is headquartered in Bengaluru, India.
Pulmocide Ltd, a company focused on the discovery and development of a new generation of inhaled medicines for the treatment of serious viral and fungal infections of the respiratory tract.
Cytek Biosciences provides solutions that enable scientists to rapidly, efficiently obtain deep biological insights through high quality, high parametric datasets. Cytek manufactures and supplies flow cytometry products and services. Cytek’s compact, affordable instruments, and wide-ranging support offerings are used by researchers and clinicians all over the world.
Cytek is focused on accelerating the adoption of flow cytometry to fuel scientific discovery. These solutions deliver deep biological insights at an affordable price, provide high-end capabilities, and bring simplified workflows to more researchers than ever before.
Core Diagnostics is a Clinical laboratory focused on Next Generation Diagnostics for disease stratification and therapy selection. We are focused on bringing the most advanced testing techniques and expertise to India. We aim to become the destination for all your high-end diagnostic needs.
Turnstone Biologics Inc., a biotechnology company, focuses on the development of viral immunotherapies to improve survival of people with cancer. Its lead candidate RIVAL-01 consists of the vaccinia virus backbone encoding three potent immunomodulators, such as Flt3 ligand, anti-CTLA-4 antibody, and IL-12 cytokine designed to work together to drive immune activity and re-program the microenvironment to be best suited for tumor eradication. The company was founded in 2015 and is based in Ottawa, Canada with an additional office in New York, New York.
Denali Therapeutics is a biopharmaceutical company based in South San Francisco, California, dedicated to discovering and developing therapies for neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). The company is advancing several therapeutic candidates, including LRRK2 inhibitors like DNL201 and DNL151, which are in various phases of clinical trials for Parkinson's disease. Additionally, Denali is developing DNL747, a selective RIPK1 inhibitor currently in Phase 1b trials for Alzheimer's and ALS. It also has programs focused on enzyme replacement therapy for MPS II and antibody transport vehicles targeting key proteins involved in neurodegeneration. Denali collaborates with various organizations, including Takeda Pharmaceutical Company and Genentech, to enhance its research efforts. Founded in 2013, Denali Therapeutics emphasizes a science-driven approach to address the complex challenges posed by neurodegenerative diseases, leveraging recent scientific insights and translational medicine tools.
US HealthVest is an innovative behavioral healthcare firm that has redefined the psychiatric hospital space. De novo strategies and acquisitions of operating facilities with unrealized potential are the core of the US HealthVest business model. Each facility is structured to offer multiple service lines in order to serve the needs of specific patient population groups. The senior management team of US HealthVest has successfully built psychiatric hospital businesses which were acquired by public companies. Ascend Health was founded by Richard Kresch, M.D. in 2005 and was one of the largest private psychiatric hospital providers with nine freestanding facilities and nearly 900 beds. Ascend Health was sold to Universal Health Services (NYSE: UHS) in 2012. The predecessor company, Heartland Health Developments, also focused on psychiatric care and was sold to Psychiatric Solutions in 2004.
Caribou Biosciences, Inc. is a biotechnology company based in Berkeley, California, specializing in cellular engineering and genome analysis through CRISPR-Cas9 technology. Founded in 2011, the company provides a gene editing platform that allows for targeted modifications in the genome. Its applications span various sectors, including human and animal therapeutics, agricultural biotechnology, and industrial biotechnology. Caribou's solutions facilitate the development of new disease models, enhance traits in plants, and support functional genomic screens. The company aims to advance both basic and applied biological research, leveraging its transformative capabilities to impact therapeutic development and bioproduction.
Quartet Health, Inc. develops and operates a cloud based platform that allows communication and collaboration between medical providers with behavioral health providers for patient care. Its platform works with health plans and health systems to provide actionable population insights and reports on behavioral health conditions to improve patient outcomes, as well as provides tools for patient self-management. The company was founded in 2014 and is based in New York, New York.
Adagene (Suzhou) Limited is a clinical-stage biotechnology company based in Suzhou, China, focused on antibody discovery and engineering. The company specializes in developing immuno-oncology antibodies that target novel epitopes, utilizing its proprietary Smart Antibody Technology. This technology enhances the success rates of antibody development, significantly shortens the time required to bring products to market, and lowers associated costs. Adagene's offerings extend beyond therapeutic applications, as its technology is also applicable in diagnostics and research, aiming to advance the field of immunotherapy and improve patient outcomes. Founded in 2011, Adagene continues to innovate in the biopharmaceutical sector.
Toast, Inc. is a Boston-based technology company that specializes in developing an all-in-one point-of-sale and restaurant management software tailored for the foodservice and hospitality industries. Founded in 2011, Toast's cloud-based platform provides a comprehensive suite of features, including tableside ordering, online ordering, labor management, and real-time reporting, designed to enhance operational efficiency for restaurants, cafes, bars, and other food establishments. The software facilitates quick menu updates and integrates front-of-house and back-of-house operations, enabling restaurants to streamline their processes and improve guest experiences. With additional offices in Portland, Omaha, and Dublin, Toast aims to support restaurateurs in delivering exceptional service and achieving business success.
VYNE Therapeutics is a late-stage biopharmaceutical company that specializes in the development and commercialization of serlopitant, a treatment for pruritus associated with various dermatologic conditions, including atopic dermatitis, psoriasis, and prurigo nodularis. The company aims to address a significant unmet medical need, as there are currently no approved therapies in the United States that specifically target pruritus in these conditions. In addition to its focus on dermatologic applications, VYNE is also investigating serlopitant for refractory chronic cough, a persistent cough that lasts more than eight weeks despite treatment. Serlopitant acts as a selective small molecule inhibitor of the neurokinin 1 receptor and is administered as an oral tablet once daily. The company has completed Phase II clinical trials for pruritus related to various conditions and is planning to advance into Phase III trials for prurigo nodularis, anticipating further data to support its clinical development. VYNE Therapeutics is headquartered in Redwood City, California, and was established in 2011.
Proteostasis Therapeutics is discovering and developing novel small molecule therapeutics designed to control the body's protein homeostasis, or Proteostasis Network. The Proteostasis Network maintains the body's natural balance of proteins to protect us from numerous diseases. These novel therapies, or Proteostasis Regulators, are designed to treat multiple genetic and degenerative disorders associated with deficiencies of the Proteostasis Network, such as emphysema, type II diabetes, Alzheimer's Disease and Huntington's Disease.
Unum Therapeutics is a biopharmaceutical company focused on developing immunotherapy products for cancer treatment, utilizing proprietary T-cell engineering technology. The company’s lead programs, based on its Antibody-Coupled T-cell Receptor (ACTR) technology, are in Phase I clinical trials. These include ACTR707 and ACTR087, both being tested in combination with rituximab for relapsed or refractory CD20+ non-Hodgkin lymphoma, as well as ACTR087 combined with SEA-BCMA for relapsed multiple myeloma. Additionally, ACTR707 is being evaluated with trastuzumab for HER2+ solid tumors. Unum Therapeutics is also exploring BOXR1030, a pre-clinical candidate targeting glypican-3 to enhance T cell functionality in the solid tumor microenvironment. Founded in 2014 and headquartered in Cambridge, Massachusetts, Unum aims to activate the body’s immune system to effectively combat cancer through its innovative therapies.
Dimension Therapeutics is a gene therapy company focused on developing novel treatments for rare diseases. Their team comprises biotech industry veterans and thought leaders in gene therapy and rare diseases.
The company is focused on advancing its platform of gene therapy programs in rare diseases through clinical development, starting with lead programs in hemophilia, and building out a world-class product engine for adeno-associated virus (AAV) therapeutics.
In conjunction with its launch, Dimension has entered into an exclusive license and collaboration with REGENX Biosciences. REGENX holds exclusive rights to a portfolio of over 100 patents and patent applications pertaining to its NAV vector technology and related applications. Through its license and collaboration with REGENX, Dimension has acquired preferred access to NAV vector technology and rights within REGENX product programs in multiple rare disease indications. Dimension has completed a Series A financing led by Fidelity Biosciences.
Mersana Therapeutics employs its biodegradable polymer platform to create new and better medicines. They are advancing their own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications.
It was founded in 2005 and headquartered in Cambridge, Massachusetts.
TraceLink, Inc. provides a comprehensive track and trace network solution designed to connect the life sciences supply chain and combat counterfeit prescription drugs. The company specializes in pharmaceutical serialization and compliance services, offering the TraceLink Life Sciences Cloud, which facilitates global connectivity and visibility throughout the pharmaceutical supply chain. Key products include the Smart Rx Manager, which helps healthcare providers comply with European Union regulations, and EU FMD Express, tailored for smaller pharmaceutical firms. Additionally, the Serialized Product Intelligence application enables users to monitor supply chain operations and address potential issues. TraceLink serves a wide range of clients, including pharmaceutical companies and wholesale distributors, and has established strategic partnerships with industry leaders. Founded in 2009 and headquartered in North Reading, Massachusetts, TraceLink has expanded its presence with offices in the United Kingdom, India, Singapore, and Brazil, and is recognized for its contributions to improving supply chain performance and reducing risks in global pharmaceutical distribution.
Recurly, Inc. develops and provides enterprise-class subscription management solutions to optimize and automate revenue growth for businesses worldwide. Its subscription management solution allows users to speed time-to-value, maximize revenue, boost developer productivity, gain actionable insights, and ensure security and compliance. The company provides subscription management solutions, deep payments expertise, and data-driven billing intelligence to optimize subscription revenue growth for businesses. Its subscription management and billing platform manage subscription revenues for companies in digital media, streaming, publishing, SaaS, consumer goods, and professional services industries. The company was incorporated in 2009 and is based in San Francisco, California. It has additional offices in Boulder, Colorado and New Orleans, Louisiana.
Aclaris Therapeutics started by the founders of Vicept Therapeutics, is a privately held specialty pharmaceutical dermatology company focused on the development of novel dermatologic therapies. It is committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in dermatology, both medical and aesthetic, and immunology. Aclaris is focused on market segments with no FDA-approved medications or where treatment gaps exist.
Xulu, Inc. provides investment advisory services. The company offers personalized and data-driven recommendations to optimize clients’ 401(k) and IRA. It also provides financial projections; and personalized diversification plans for investments. The company was founded in 2010 and is based in Seattle, Washington. As of October 1, 2015, FutureAdvisor operates as a subsidiary of BlackRock, Inc.
Blueprint Medicines Corporation focuses on developing small molecule kinase inhibitors aimed at treating genomic drivers in cancers, rare diseases, and enhancing cancer immunotherapy. The company is advancing several key drug candidates, including avapritinib for systemic mastocytosis and gastrointestinal stromal tumors, BLU-263 for indolent systemic mastocytosis and other mast cell disorders, and fisogatinib for advanced hepatocellular carcinoma, currently in Phase I clinical trials. Additionally, pralsetinib targets RET-altered non-small cell lung cancer and other solid tumors, while BLU-782 is being investigated for fibrodysplasia ossificans progressive. Founded in 2008 and headquartered in Cambridge, Massachusetts, Blueprint Medicines emphasizes the development of personalized cancer therapies by leveraging insights into cancer genomics and utilizing a proprietary chemical library to identify new therapeutic compounds. The company collaborates with various partners, including Clementia Pharmaceuticals and Genentech, to enhance its research and development efforts.
Flywire operates an online payment platform that facilitates both domestic and international transactions, catering primarily to the education and healthcare sectors. The platform enables users, including international students and patients seeking medical care abroad, to make payments in various currencies through familiar online and offline options. By leveraging vertical-specific insights and technology, Flywire streamlines the payment process and enhances operational efficiency while minimizing risks associated with invoicing and payment reconciliation. The company, which was founded in 2009 and is headquartered in Boston, Massachusetts, has established partnerships with TRUE North and Adyen to bolster its offerings. With a significant portion of its revenue generated from the Americas, Flywire continues to expand its services to meet the needs of its diverse clientele.
Acacia Pharma is a hospital pharmaceutical company based in Cambridge, United Kingdom, that specializes in the discovery, development, and commercialization of supportive care drugs for patients undergoing surgery, invasive procedures, or cancer treatments. The company’s lead product, BAREMSIS, is an intravenous formulation of amisulpride designed to prevent and treat post-operative nausea and vomiting. Other notable products include APD403, which has completed Phase II trials for chemotherapy-induced nausea and vomiting, and BYFAVO, an ultra-short-acting intravenous benzodiazepine anesthetic that has completed Phase III trials for use in procedures like colonoscopy and bronchoscopy. Acacia Pharma primarily serves anesthesiologists and oncologists, with a focus on addressing issues related to nausea, vomiting, cancer-related fatigue, and cachexia. Established in 2006, the company continues to innovate in the field of cancer supportive care.
Iora Health, Inc. operates a primary care healthcare system in the United States, focusing on providing comprehensive care to patients, particularly college employees and their adult dependents. Founded in 2010 and headquartered in Boston, Massachusetts, the organization emphasizes personalized care by assigning each patient a dedicated physician and a health coach. This team facilitates continuous support through various communication methods, including email, text, and video, alongside in-person visits. Iora Health also offers educational programs, such as group visits, aimed at empowering patients to manage their health effectively and achieve their health goals. The company is dedicated to removing barriers in the healthcare system, ensuring that patients receive the attention and resources they need to navigate their health journeys successfully.
Kyruus, Inc. develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010 and headquartered in Boston, Massachusetts, the company offers a range of analytically driven tools designed to enhance the engagement and management of large physician networks. Key products include Kyruus Passport, which tracks physician productivity and performance, and Kyruus Profiles, which provides administrators with insights into physician activity. Additionally, Kyruus MDSeekyr helps users identify high-value providers, while Kyruus Insight Reports enables executives to analyze physician network performance over time. The company's ProviderMatch suite further enhances patient-provider matching and streamlines the scheduling process, ensuring a consistent patient experience across various access points. By leveraging big data, Kyruus aims to align provider supply with patient demand effectively.
Ultragenyx Pharmaceutical develops therapeutics for rare diseases, sometimes referred to as Orphan products. Ultragenyx is a efficient and effective development strategies are essential for success in the rare disease space, in which information may be incomplete or ambiguous, and few development precedents exist. The management team's experience in selecting and developing products with clear mechanisms of action for untreated rare diseases will help Ultragenyx create life-changing therapeutics by leveraging existing yet undeveloped science for these little-known indications.
Innovent Biologics, Inc. is a prominent biopharmaceutical company based in Suzhou, China, specializing in the discovery, development, manufacture, and commercialization of monoclonal antibody drug candidates. The company focuses on various therapeutic areas, including oncology, ophthalmology, immunology, and metabolic diseases. Its flagship product, Tyvyt (sintilimab), is an anti-PD-1 monoclonal antibody used in treating multiple cancers and is featured on the National Reimbursement Drug List. Innovent has developed several other promising candidates, including biosimilars and bispecific antibodies for conditions such as non-Hodgkin’s lymphoma, autoimmune diseases, and advanced solid tumors. The company has established strategic collaborations with major global pharmaceutical firms, enhancing its research and development capabilities. Founded in 2011, Innovent has a strong management team with extensive experience in biologics, and it continues to expand its portfolio of therapeutic options while maintaining a commitment to innovation in the biopharmaceutical industry.
Eris Exchange is a U.S. futures exchange based in Chicago, Illinois, that operates as a Designated Contract Market registered with the Commodity Futures Trading Commission (CFTC). The exchange specializes in USD cash-settled interest rate swap futures, which are traded electronically on the Eris SwapBook and cleared through CME Clearing. Eris Exchange also develops and offers digital currency products, including spot and futures contracts for various cryptocurrencies such as bitcoin, bitcoin cash, ethereum, and litecoin. Additionally, its subsidiary, Eris Innovations LLC, focuses on intellectual property licensing and the design of swap futures products. The exchange has established a significant presence in the market, with a current open interest exceeding 180,000 contracts in its USD Interest Rate Swap Futures.
NeuroTherapeutics Pharma, Inc., a biopharmaceutical company, develops therapeutics for patients suffering from central nervous system disorders. It focuses on epilepsy, neuropathic, and acute pain disorders of the nervous system. The company was incorporated in 2006 and is based in Chicago, Illinois.
Tetraphase Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing novel antibiotics to combat serious multidrug-resistant infections. Its primary product candidate, Xerava (eravacycline), is a synthetic fluorocycline designed for intravenous use as a first-line treatment for multidrug-resistant infections, particularly those caused by Gram-negative bacteria. The company has conducted Phase III clinical trials, including IGNITE1 and IGNITE4, to evaluate Xerava's safety and efficacy for treating complicated intra-abdominal infections. In addition to Xerava, Tetraphase is advancing other product candidates, such as TP-271, which targets respiratory diseases caused by antibiotic-resistant pathogens, and TP-6076, aimed at treating multidrug-resistant Gram-negative infections. The company holds a licensing agreement with Everest Medicines Limited to develop and commercialize Xerava in various Asian markets. Founded in 2006 and headquartered in Watertown, Massachusetts, Tetraphase Pharmaceuticals is a subsidiary of La Jolla Pharmaceutical Company.
ViewRay, Inc. specializes in the design, manufacture, and marketing of advanced radiation therapy systems, particularly the MRIdian system, which is the first MRI-guided radiation therapy technology that allows simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology with radiation delivery and proprietary software, enabling clinicians to accurately locate, target, and track soft-tissue tumors during treatment. By providing real-time imaging, MRIdian enhances visibility of tumors, thus allowing for precise radiation delivery while minimizing exposure to surrounding healthy tissue. This capability addresses significant limitations of traditional external-beam radiation therapies and expands treatment options for patients who may not have been eligible for radiation therapy previously. ViewRay serves a diverse client base, including university hospitals, community hospitals, and freestanding cancer centers, through a direct sales force and distribution network. The company, founded in 2004 and headquartered in Oakwood, Ohio, has operations in the United States and several European countries.
FoldRx Pharmaceuticals, Inc. engages in the discovery and development of disease modifying drug therapies for diseases of protein misfolding and amyloidosis. The companyТs pipeline includes a program in advanced clinical development to treat genetic neurologic and cardiovascular disorders, transthyretin-associated amyloidoses with polyneuropathy and TTR-associated amyloidoses with cardiomyopathy, and a discovery program in Parkinson's disease and cystic fibrosis. FoldRx Pharmaceuticals, Inc. was founded in 2003 and is based in Cambridge, Massachusetts.